CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has appointed John A. Schmidt, Jr., M.D. to the position of Chief Scientific Officer. In this role, Dr. Schmidt will play a critical role in leading Alnylam's research and drug discovery activities, and will report to John Maraganore, Alnylam’s Chief Executive Officer.
